The synthesis of this valuation gap requires understanding market dynamics. Investors assign premium multiples to companion animal health businesses (like Idexx Laboratories or the companion

Adyen (ADYEN.AS): A dominant European horizontal player trading at significantly higher growth multiples—commanding a ~5.0x EV/Revenue multiple and ~21.6x forward EV/EBITDA [cite: 1, 2]—largely due

Disclaimer: This report provides deep-dive equity analysis, valuation metrics, and forward-looking financial commentary. It is for informational purposes only and does not constitute professional, financial,